|Citation: Pecoits-Filho R, Rosa-Diez G, Gonzalez-Bedat M, Marinovich S, Fernandez S, Lugon J, et al. Renal Replacement Therapy in CKD: an update from the Latin American Registry of Dialysis and Transplantation . Braz. J. Nephrol. (J. Bras. Nefrol.) 37(1):09. doi:10.5935/0101-2800.20150002|
|Received: Outubro 05 2014; Accepted: Outubro 08 2014|
Latin America (LA) is the region of the Americas stretching from Mexico and the Caribbean Islands to Argentina and Chile in the South. The common features of countries in the region are that they share common languages (Spanish and Portuguese) and have a large ethnic diversity. The region's populations are made up from an ethnic fusion process in which the original immigrants from Spain and Portugal were mixed with Europeans, especially during the World Wars, Native Americans (mainly in Bolivia, Guatemala, Peru and Mexico) and the descendants of African slaves (especially in Brazil, Colombia and Uruguay). The mixture of races is so large (for example, in Brazil) that genetic studies have concluded that it is not possible to identify one race according to skin color. Most of these people are usually mulatto and paternal genes come from the Spanish or Portuguese peoples.1,2
The region has undergone a rapid process of demographic and epidemiological transition, characterized by reduced birth and mortality rates, concurrent with rapid changes in lifestyle. This came together with the population movement from rural areas to the cities, causing an increase in "non-transmissible" diseases, coexisting with infectious diseases such as dengue and Chagas disease. From the socioeconomic point of view, significant improvements have occurred in the past 10 years, such as the increase in per capita income from US$ 3,683 in 2001 to US$ 7,821 in 2010, and the increase in life expectancy at birth, from 71.6 in 2000 to 74 in 2010.3-5
The Latin American Dialysis and Renal Transplantation Registry (RLDTR) began operations in 1991, collecting data from 20 countries - members of the Latin American Society of Nephrology and Hypertension (SLANH) and publishing successive reports since 1993.6-11 This report, published in its entirety recently,12 brings the latest results from the year 2010.
The detailed methodology was described in previous reports.6-11 Participating countries fill out an annual report form concerning the incidence and prevalence of chronic kidney disease (CKD), specifically in stage 5 - those in renal replacement therapy (RRT) under hemodialysis (HD), peritoneal dialysis (PD) and kidney transplantation (Tx). It also includes information on the number of dialysis and transplantation centers. Based on these data, they establish the incidence and prevalence rates as of December 31 of each year, expressed as patients per million of the population (pmp). Then, they compare incidence and prevalence rates with those from previous years and analyze treatment modalities with special emphasis on HD vs. PD and functioning renal transplant (Tx).
This report involved 20 countries with a population representing 99% of that in Latin America. Table 1 describes the most important variables analyzed. RRT prevalence in LA increased from 119 patients per million of the population (pmp) in 1991 to 660 pmp in 2010 (HD 392 pmp, pmp PP 129 and Tx 105 pmp) (Figure 1). The highest rates were reported by Puerto Rico (1355 pmp); Argentina, Mexico, Uruguay and Chile, with rates between 777 and 1,136 pmp, respectively.
|Country||*Population in millions||GDP||**Life expectancy at birthr||Total number of patients in RRT||Number of patients in HD||Number of patients in PD||% of patients in PD||Number of patients with functioning transplant||HD prevalence rate pmp||PD prevalence rate pmp||Dialysis prevalence rate (HD + PD) pmp||Tx prevalence rate pmp||RRT prevalence rate pmp|
Although there was an increase in all RRT modalities, HD increased proportionally more than PD and Tx (Figure 2). The growth of these modalities compared to 2008 was 20%, 14% and 5% for HD, PD and Tx, respectively. HD is the treatment of choice in the region (75%). PD is more commonly used only in El Salvador and Mexico (67.6% and 55.9%, respectively); also prevalent in Colombia, although the percentage of patients on PD in that country has declined in the last 10 years from 54% in 2000 to 31% in 2010.
The Tx rate went from 3.7 in 1987 to 18.5 in 2010 (Figure 3), albeit with significant variations this year (28.2 pmp in Argentina to 0.5 pmp in Honduras). Because of its large population, there has been a high absolute number registered in Brazil (4,630 transplants performed in 2010); in addition to 197 pancreatic transplants performed in the region: 129 in Brazil, 58 in Argentina, 4 in Uruguay, 3 in Colombia, one in Cuba, one in Chile and one in Peru. The total number of transplants was 10,397 in 2010, with 58% coming from deceased donors, with the highest rates coming from Uruguay (96.8%), Cuba (94.9%), Colombia (92%) and Argentina (78,7%) (Figure 4).
The overall prevalence of RRT was directly correlated with gross domestic product (GDP) (r2 0.86; p < 0.05) and life expectancy at birth (r2 0.58; p < 0.05) (Figures 5 and 6). The prevalence of HD and Tx was also significantly correlated with the same indexes, while PD was not correlated with these variables. Thirteen countries reported incidence rates, representing 87% of the Latin American population (Table 1). There is a large incidence variation of 458 in Mexico and 10.7 pmp in Guatemala. Most countries in the region show either a stabilization trend or a minimal growth rate, except in Ecuador, where they had a significant growth in their incidence rate (38 in 2008 to 127 pmp in 2010). As in previous reports, the overall incidence rate was significantly correlated with GDP (r2 0.63; p < 0.05).
Diabetes remains a major cause of CKD in RRT, with the highest incidences recorded in Puerto Rico (66.8%), Mexico (61.8%) and Colombia (42.5%) and the lowest incidences reported by Cuba (26.2%) and Uruguay (23.2%). The incidence of diabetes did not correlate with GDP or life expectancy at birth. The most frequent causes of death were cardiovascular (45%) and infectious (22%), while cancer accounted for 10% of all death causes.
This report shows that the prevalence of CKD in RRT continues to increase in the region, particularly in countries that have universal public healthcare coverage. In these countries, where the incidence tends to stabilize or grow slowly, the increased prevalence is probably the result of an increase in life expectancy in the general population and the survival of patients on RRT. The incidence continues to grow, both in countries that have not yet achieved universal RRT coverage for the population and in those with an appropriate program of early detection and treatment of CKD and its associated risk factors.
PD is still an underutilized RRT mode in the region, in contrast to the continued expansion of HD - which is probably due to several factors, including the shortage of nephrologists and trained nurses, lack of health policies and financial support to promote this type of treatment. This treatment modality could be useful to overcome the difficulties that geographical conditions impose on some patients who need to travel long distances to access treatment in remote areas of large cities.
Although kidney transplant is available and increasingly used in Latin America, its growth was not as fast as it should be to compensate for the increased prevalence of patients on the waiting list. Whereas diabetes and hypertension remain the most common causes of admission to dialysis, CKD prevention programs should include early diagnosis and appropriate treatment of these diseases.
In most countries in the region, reporting on local registers is voluntary, generating great variability in the consistency of RLADTR data. For instance, the Mexican data is extrapolated from regional registries (Morelos state and Guadalajara) and the number of patients on RRT is estimated. In Brazil, although there is a recent initiative of organizing a National Register, the data comes from the Brazilian Dialysis Census - of voluntarily participation from both patients and clinics, thus generating estimate data.13
Finally, the RLADTR has strengths, among which we should emphasize its continuity over time since its inception in 1991, its contribution to the development of national registers, allowing comparisons between different countries and other regional registries, as well as enabling CKD in RRT trend analyzes in Latin America.
In short, diabetes and hypertension prevention and diagnosis programs, the implementation of appropriate policies to promote and allow PD expansion as well as the implementation of effective organ collection and Tx programs are needed in Latin America for further advances in the treatment of CKD. Cooperation between countries in the region, enabling the continuous annual data analysis, as well as the training of professionals in the implementation of registers in countries where they are not yet implemented, are the main objectives of RLADTR for the coming years.